
|Articles|July 10, 2015
- Gastrointestinal Cancers (Issue 5)
- Volume 4
- Issue 2
Surivival Benefit of Regorafenib in CORRECT and CONCUR Trials
Author(s)Axel Grothey, MD
Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses the survival benefit of regorafenib in CORRECT and CONCUR trials.
Advertisement
Articles in this issue
over 10 years ago
Prevention and Screening of CRCover 10 years ago
Survival Differences in KRAS/BRAF Mutations in mCRCover 10 years ago
New Agents Show Potency for Patients with HCCover 10 years ago
Success of Regorafenib Confirmed in Patients With mCRCover 10 years ago
Agents Under Examination Demonstrate Success in Gastric CancerAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
4
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
5



















